Abstract
Toll-like receptors (TLRs) are a family of key proteins that permit mammals to detect microbes and endogenous molecules, which are present in body fluids, cell membranes and cytoplasm. They confer mechanisms to the host for maintaining homeostasis, activating innate immunity and inducing signals that lead to the activation of adaptive immunity. TLR signalling induces the expression of pro-inflammatory and anti-viral genes through different and intricate pathways. However, persistent signalling can be dangerous and all members of the TLR family are involved in the pathogenesis of acute and chronic inflammation, autoimmunity, allergy, cancer and aging. The pharmaceutical industry has begun intensive work developing novel immunotherapeutic approaches based on both activation and inhibition of TLR triggering. Further, clinical trials are pending to evaluate TLR agonists as novel vaccine adjuvants and for the treatment of infectious diseases, allergic diseases and asthma. Since systemic, metabolic and neuroendocrine changes are elicited by inflammation, TLR activity is susceptible of regulation by hormones and neuroendocrine factors. Neuroendocrine mediators are important players in modulating different phases of TLR regulation contributing to the endogenous control of homeostasis through local, regional and systemic routes. Vasoactive intestinal peptide (VIP) is an important signal molecule of the neuroendocrine-immune network that has recently emerged as a potential candidate for the treatment of inflammatory and autoimmune disorders by controlling innate and adaptive immunity. This review shows current advances in the understanding of TLR modulation by VIP that could contribute to the use of this natural peptide as a therapeutic tool.
Keywords: TLR, neuropeptides, VIP, autoimmunity, inflammation, immunotherapy, drug design
Current Pharmaceutical Design
Title: Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics
Volume: 16 Issue: 9
Author(s): Rosa P. Gomariz, Irene Gutierrez-Canas, Alicia Arranz, Mar Carrion, Yasmina Juarranz, Javier Leceta and Carmen Martinez
Affiliation:
Keywords: TLR, neuropeptides, VIP, autoimmunity, inflammation, immunotherapy, drug design
Abstract: Toll-like receptors (TLRs) are a family of key proteins that permit mammals to detect microbes and endogenous molecules, which are present in body fluids, cell membranes and cytoplasm. They confer mechanisms to the host for maintaining homeostasis, activating innate immunity and inducing signals that lead to the activation of adaptive immunity. TLR signalling induces the expression of pro-inflammatory and anti-viral genes through different and intricate pathways. However, persistent signalling can be dangerous and all members of the TLR family are involved in the pathogenesis of acute and chronic inflammation, autoimmunity, allergy, cancer and aging. The pharmaceutical industry has begun intensive work developing novel immunotherapeutic approaches based on both activation and inhibition of TLR triggering. Further, clinical trials are pending to evaluate TLR agonists as novel vaccine adjuvants and for the treatment of infectious diseases, allergic diseases and asthma. Since systemic, metabolic and neuroendocrine changes are elicited by inflammation, TLR activity is susceptible of regulation by hormones and neuroendocrine factors. Neuroendocrine mediators are important players in modulating different phases of TLR regulation contributing to the endogenous control of homeostasis through local, regional and systemic routes. Vasoactive intestinal peptide (VIP) is an important signal molecule of the neuroendocrine-immune network that has recently emerged as a potential candidate for the treatment of inflammatory and autoimmune disorders by controlling innate and adaptive immunity. This review shows current advances in the understanding of TLR modulation by VIP that could contribute to the use of this natural peptide as a therapeutic tool.
Export Options
About this article
Cite this article as:
Gomariz P. Rosa, Gutierrez-Canas Irene, Arranz Alicia, Carrion Mar, Juarranz Yasmina, Leceta Javier and Martinez Carmen, Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics, Current Pharmaceutical Design 2010; 16 (9) . https://dx.doi.org/10.2174/138161210790963841
DOI https://dx.doi.org/10.2174/138161210790963841 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Fibrosis in Systemic Sclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Anaphylaxis: An Update on its Understanding and Management
Recent Patents on Inflammation & Allergy Drug Discovery Recent Updates on the Systemic and Local Safety of Intranasal Steroids
Current Drug Metabolism Type 1 11 β-hydroxysteroid Dehydrogenase as Universal Drug Target in Metabolic Diseases?
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Targets for Modulating Lung Inflammation and Injury
Current Drug Targets CCR1 Antagonists: What Have We Learned From Clinical Trials
Current Topics in Medicinal Chemistry Potential Association Between TLR4 and Chitinase 3-Like 1 (CHI3L1/YKL-40) Signaling on Colonic Epithelial Cells in Inflammatory Bowel Disease and Colitis-Associated Cancer
Current Molecular Medicine Choline Alphoscerate (Alpha-Glyceryl-Phosphoryl-Choline) An Old Choline- containing Phospholipid with a Still Interesting Profile As Cognition Enhancing Agent
Current Alzheimer Research Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer
Current Pharmaceutical Design Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design Pharmacological Treatment of Obstructive Sleep Apnea
Current Pharmaceutical Design Vegetable Oil: Nutritional and Industrial Perspective
Current Genomics Rho Kinase (ROCK) Inhibitors and Their Application to Inflammatory Disorders
Current Topics in Medicinal Chemistry Influenza Antiviral Therapeutics
Recent Patents on Anti-Infective Drug Discovery Allosteric Enhancers for A1 Adenosine Receptor
Mini-Reviews in Medicinal Chemistry Chronotherapeutic Drug Delivery from Indomethacin Compression Coated Tablets for Early Morning Pain Associated Rheumatoid Arthritis
Current Drug Delivery G Protein-Coupled Receptors: Target-Based In Silico Screening
Current Pharmaceutical Design Appraisal of Anti-Arthritic and Anti-Inflammatory Potential of Folkloric Medicinal Plant <i>Peganum harmala</i>
Endocrine, Metabolic & Immune Disorders - Drug Targets Comparison of Clinical Characteristics, Laboratory Findings and Imaging Manifestations of COVID-19 in Sulfur Mustard-exposed Survivors and Others: a Case-control Study
Current Drug Therapy Study of SARS-nCoV2 Indian Isolates Gaining Insights into Mutation Frequencies, Protein Stability and Prospective Effect on Pathogenicity
Coronaviruses